Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk has filed a citizen petition with the FDA to block the compounding of liraglutide, a key ingredient in its diabetes and obesity medications, by outsourcing facilities. The move ...

Liraglutide, also owned by Novo Nordisk®, is the world's 3 rd most popular glucagon-like peptide-1 ("GLP-1") or glucose-dependent insulinotropic ("GIP") weight loss/diabetes drug on the market today.

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

and liraglutide, Novo Nordisk says it is confident of the risk-benefit profile of these agents. Medscape Medical News, July 12, 2023 Weighing Childhood Obesity Interventions The growing number of ...